New injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy.
Boehringer Ingelheim Vetmedica has launched Vetmedin 0.75 mg/ml Solution for Injection for dogs.
The new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM).
Twelve hours after the injection is administered treatment can then be continued by the dog’s owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
RCVS recognised cardiology specialist Ruth Willis explained: “Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM.”
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25kg.
To support the launch of Vetmedin Solution for Injection, Boehringer is hosting a complimentary cardiology webinar presented by Ruth Willis entitled “Acute CHF – a stress free approach”. The informative online seminar takes place at 8pm on February 19, 2013, and counts for one hour’s CPD.
Places are limited, but the webinar will be available to view “on demand” after the live event.
- Register for the cardiology webinar online
- For further information on the Vetmedin range, point of sale material or the cardiology webinar contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.